DK2630263T3 - Varital tælling af nucleinsyrer for at opnå information om antal genomiske kopier - Google Patents
Varital tælling af nucleinsyrer for at opnå information om antal genomiske kopier Download PDFInfo
- Publication number
- DK2630263T3 DK2630263T3 DK11835243.4T DK11835243T DK2630263T3 DK 2630263 T3 DK2630263 T3 DK 2630263T3 DK 11835243 T DK11835243 T DK 11835243T DK 2630263 T3 DK2630263 T3 DK 2630263T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleic acid
- acid molecules
- genome
- labeled nucleic
- genomic
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 250
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 243
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 243
- 241000718423 Drypetes glauca Species 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract description 147
- 238000012163 sequencing technique Methods 0.000 claims abstract description 89
- 230000003321 amplification Effects 0.000 claims abstract description 75
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 75
- 239000000463 material Substances 0.000 claims abstract description 58
- 238000003752 polymerase chain reaction Methods 0.000 claims abstract description 55
- 238000006243 chemical reaction Methods 0.000 claims abstract description 48
- 238000013507 mapping Methods 0.000 claims abstract description 18
- 239000000523 sample Substances 0.000 claims description 109
- 108091033319 polynucleotide Proteins 0.000 claims description 58
- 102000040430 polynucleotide Human genes 0.000 claims description 58
- 239000002157 polynucleotide Substances 0.000 claims description 58
- 239000002299 complementary DNA Substances 0.000 claims description 55
- 108020004999 messenger RNA Proteins 0.000 claims description 46
- 230000000295 complement effect Effects 0.000 claims description 40
- 230000015572 biosynthetic process Effects 0.000 claims description 25
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 claims description 19
- 102100029764 DNA-directed DNA/RNA polymerase mu Human genes 0.000 claims description 19
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 15
- 238000012408 PCR amplification Methods 0.000 claims description 9
- 238000002372 labelling Methods 0.000 claims description 7
- 230000001915 proofreading effect Effects 0.000 claims description 5
- 239000013074 reference sample Substances 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims 14
- 210000004027 cell Anatomy 0.000 description 103
- 108020004414 DNA Proteins 0.000 description 97
- 125000003729 nucleotide group Chemical group 0.000 description 40
- 239000002773 nucleotide Substances 0.000 description 39
- 239000012634 fragment Substances 0.000 description 37
- 206010028980 Neoplasm Diseases 0.000 description 34
- 239000000203 mixture Substances 0.000 description 25
- 201000011510 cancer Diseases 0.000 description 19
- 230000008569 process Effects 0.000 description 17
- 241000894007 species Species 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 17
- 108091008146 restriction endonucleases Proteins 0.000 description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 15
- 238000004458 analytical method Methods 0.000 description 15
- 239000003153 chemical reaction reagent Substances 0.000 description 15
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 13
- 238000009396 hybridization Methods 0.000 description 13
- 238000002493 microarray Methods 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 12
- 239000000758 substrate Substances 0.000 description 11
- 238000013412 genome amplification Methods 0.000 description 10
- 230000007067 DNA methylation Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 230000011987 methylation Effects 0.000 description 9
- 238000007069 methylation reaction Methods 0.000 description 9
- 238000012545 processing Methods 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000011176 pooling Methods 0.000 description 8
- 238000001712 DNA sequencing Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 210000000349 chromosome Anatomy 0.000 description 6
- 230000029087 digestion Effects 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 238000010008 shearing Methods 0.000 description 6
- 108091029523 CpG island Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000011218 segmentation Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000000527 sonication Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 3
- 208000037323 Rare tumor Diseases 0.000 description 3
- 101000690736 Triticum aestivum Agglutinin isolectin 1 Proteins 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000012165 high-throughput sequencing Methods 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000000638 solvent extraction Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 101100149536 Caenorhabditis elegans skn-1 gene Proteins 0.000 description 2
- 208000037051 Chromosomal Instability Diseases 0.000 description 2
- 108091029430 CpG site Proteins 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 102000052510 DNA-Binding Proteins Human genes 0.000 description 2
- 101710096438 DNA-binding protein Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 102000006890 Methyl-CpG-Binding Protein 2 Human genes 0.000 description 2
- 108010072388 Methyl-CpG-Binding Protein 2 Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 101100083855 Rattus norvegicus Pou2f3 gene Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000000126 in silico method Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 238000011392 neighbor-joining method Methods 0.000 description 2
- 230000000683 nonmetastatic effect Effects 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037452 priming Effects 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 206010006272 Breast mass Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 208000035970 Chromosome Breakpoints Diseases 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102000004533 Endonucleases Human genes 0.000 description 1
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 description 1
- 102100033420 Keratin, type I cytoskeletal 19 Human genes 0.000 description 1
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 description 1
- 108010066327 Keratin-18 Proteins 0.000 description 1
- 108010066302 Keratin-19 Proteins 0.000 description 1
- 108010070511 Keratin-8 Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102100023801 Somatostatin receptor type 4 Human genes 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000026487 Triploidy Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000004115 adherent culture Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 101150118588 alx gene Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000001369 bisulfite sequencing Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000018732 detection of tumor cell Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000012268 genome sequencing Methods 0.000 description 1
- 238000011331 genomic analysis Methods 0.000 description 1
- 229940079826 hydrogen sulfite Drugs 0.000 description 1
- -1 hydrogensulfite compound Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000007854 ligation-mediated PCR Methods 0.000 description 1
- LPHFLPKXBKBHRW-UHFFFAOYSA-L magnesium;hydrogen sulfite Chemical compound [Mg+2].OS([O-])=O.OS([O-])=O LPHFLPKXBKBHRW-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 102000031635 methyl-CpG binding proteins Human genes 0.000 description 1
- 108091009877 methyl-CpG binding proteins Proteins 0.000 description 1
- 238000012164 methylation sequencing Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- GWCQNKRMTGVYIZ-UHFFFAOYSA-N n-naphthalen-1-yl-1-pentylindole-3-carboxamide Chemical compound C12=CC=CC=C2N(CCCCC)C=C1C(=O)NC1=CC=CC2=CC=CC=C12 GWCQNKRMTGVYIZ-UHFFFAOYSA-N 0.000 description 1
- 238000007857 nested PCR Methods 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 108010064556 somatostatin receptor subtype-4 Proteins 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000001447 template-directed synthesis Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
- C12Q1/683—Hybridisation assays for detection of mutation or polymorphism involving restriction enzymes, e.g. restriction fragment length polymorphism [RFLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Computational Biology (AREA)
- Evolutionary Biology (AREA)
- Medical Informatics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Theoretical Computer Science (AREA)
- Cell Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Management, Administration, Business Operations System, And Electronic Commerce (AREA)
- Saccharide Compounds (AREA)
Claims (16)
1. Fremgangsmåde til opnåelse af information om antallet af genomiske kopier der ikke er påvirket af forvrængninger af amplifikation, i et genomisk materiale, hvilken fremgangsmåde omfatter: a) at opnå segmenter af det genomiske materiale; b) at mærke segmenterne med nucleinsyremarkører for at danne unikt mærkerede nucleinsyremolekyler, således at hvert af de unikt mærkede nucleinsyremolekyler omfatter et segment af det genomiske materiale ifølge trin (a) og en markør; c) at udsætte de mærkede nucleinsyremolekyler for en amplifikation ved polymerasekædereaktion (PCR); d) at generere markør-associerede sekvensreads ved at sekventere produktet ifølge trin (c); e) at tildele hvert mærket nucleinsyremolekyle et sted på et genom der er forbundet med det genomiske materiale, ved at kortlægge undersekvensen af hvert markør-associeret sekvensread, der svarer til et segment af det genomiske materiale på et sted på genomet; og f) at tælle antallet af mærkede nucleinsyremolekyler der omfatter en anden markør, som er blevet tildelt det samme sted på genomet, for derved at opnå information om antallet af genomiske kopier der ikke er påvirket af forvrængninger af amplifikation.
2. Fremgangsmåden ifølge krav 1, der yderligere omfatter at estimere et antal genomiske kopier i et område af genomet, der omfatter mere end et sted på genomet, ved at tildele antallet af kopier for området det højeste antal der er opnået ifølge trin (f) for stederne inden for området.
3. Fremgangsmåden ifølge krav 1 der yderligere omfatter at sammenligne en tælling som er opnået ifølge trin (f) for et sted på genomet, med en tælling for det samme sted der er opnået fra en referenceprøve, for derved at estimere et relativt antal genomisk kopier for stedet.
4. Fremgangsmåden ifølge krav 1, der yderligere omfatter g) at summere de opnåede tællinger ifølge trin (f) for steder på genomet, som omfatter et første område af genomet, hvor det første område omfatter mere end et sted; h) at summere de opnåede tællinger ifølge trin (f) for steder på genomet, som omfatter et andet område af genomet, hvilket andet område består af et antal steder, som kan sammenlignes med antallet af steder i det første område; i) at sammenligne værdien der er opnået ifølge trin (g) med værdien, der er opnået ifølge trin (h), for derved at estimere det relative antal genomiske kopier af det første område af genomet i forhold til antallet af genomiske kopier af det andet område af genomet.
5. Fremgangsmåden ifølge krav 4, hvor trin (h) yderligere omfatter: j) at summere de opnåede tællinger ifølge trin (f) for steder på genomet, som omfatter et tredje område af genomet, hvor det tredje område består af et antal steder, der kan sammenlignes med antallet af steder i det første område; og k) at opnå et gennemsnit af summen af de opnåede tællinger ifølge trin (f) for steder, der omfatter det andet område, og summen af de opnåede tællinger ifølge trin (f) for steder, der omfatter det tredje område.
6. Fremgangsmåden ifølge krav 4, hvor det andet område af genomet omfatter et centromer.
7. Fremgangsmåden ifølge krav 1, der yderligere omfatter at summere de opnåede tællinger ifølge trin (f) for steder, som omfatter et område af genomet, og at sammenligne summen med en sum der er opnået fra en referenceprøve for det samme område af genomet, for derved at estimere et relativt antal genomiske kopier for området af genomet.
8. Fremgangsmåde til opnåelse af information om antallet af mRNA-kopier fra mRNA-transkripter der ikke er påvirket af forvrængninger af amplifikation, hvilken fremgangsmåde omfatter: a) at generere unikt mærkede nucleinsyremolekyler, der omfatter: i) at udsætte mRNA-transkripter for en polymerasekædereaktion under betingelser, der fremmer dannelsen af kun ét komplement, hvorved der genereres derivatstrenge af første orden; ii) at tilsætte en polynukleotid-ende til derivatstrengene af første orden; og iii) at udsætte derivatstrengene af første orden for en polymerasereakti-on i nærvær af primere, der er i stand til at hybridisere til polynukleotid-enden der er tilsat ifølge trin (ii) under betingelser, som fremmer dannelsen af kun ét komplement, for derved at generere derivatstrenge af anden orden, hvor primerne ifølge mindst et af trin (i) og (iii) omfatter nucleinsyremarkører, således at hvert mærket nucleinsyremolekyle er unikt, for derved at danne unikt mærkede nucleinsyremolekyler; b) at udsætte de mærkede nucleinsyremolekyler for polymerasekædereaktion (PCR) amplifikation; c) at generere markør-associerede sekvensreads ved at sekventere produktet ifølge trin (b); d) at tildele hvert mærket nucleinsyremolekyler et sted på et cDNA-bibliotek der er associeret med mRNA-transkripterne, ved at kortlægge undersekvensen af hver markør-associeret sekvensread, der svarer til et mRNA-transkript et sted på cDNA-biblioteket; og e) at tælle antallet af mærkede nucleinsyremolekyler med en anden markør, der er blevet tildelt samme sted på cDNA-biblioteket, for derved at opnå information om antallet af mRNA-kopier der ikke er påvirket af forvrængninger af amplifikation.
9. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, hvor mærkning af segmenterne for at danne mærkede nucleinsyremolekyler omfatter: (i) at tilsætte en polynukleotid-ende til enderne af segmenterne af det genomiske materiale for at danne derivatstrenge af nulte orden; (ii) at udsætte derivatstrengene af nulte orden ifølge trin (i) for en poly-merasereaktion i nærvær af primere, der er i stand til at hybridisere til polynukleotid-enden af strengene af nulte orden under betingelser, som fremmer dannelsen af kun ét komplement, for derved at generere derivatstrenge af første orden; (iii) at tilsætte en polynukleotid-ende til derivatstrengene af første orden; (iv) at udsætte derivatstrengene af første orden for en polymerasereak-tion i nærvær af primere, der er i stand til at hybridisere til polynukleotid-enden af derivatstrengene af første orden under betingelser, der fremmer dannelsen af kun ét komplement, hvorved der genereres derivatstrenge af anden orden, hvor primerne ifølge mindst et af trin (ii) og (iv) omfatter nucleinsyremarkører, således at hvert mærket nucleinsyremolekyle er unikt, for derved at danne unikt mærkede nucleinsyremolekyler.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 1-7, hvor mærkning af segmenterne for at danne mærkede nucleinsyremolekyler omfatter: i) at tilsætte en polynukleotid-ende til enderne af segmenterne af geno-misk materiale for at danne derivatstrenge af nulte orden, ii) at udsætte derivatstrengene af nulte orden ifølge trin (i) for en ligationsreaktion i nærvær af primere, der er i stand til at hybridisere til polynukleotid-enden af derivatstrengene af nulte orden der er tilsat ifølge trin (i) under betingelser, der fremmer ligationen af en primer til 5'-enderne af derivatstrengene af nulte orden, iii) at udsætte produktet ifølge trin (ii) for en polymerasereaktion i nærvær af primere der er i stand til at hybridisere til polynukleotid-enden, som er tilsat ifølge trin (i) under betingelser, der fremmer dannelsen af kun ét komplement, hvor primerne ifølge trin (iii) har forskellige nuc-leotidsekvenser end primerne ifølge trin (ii), og hvor polymerasen har 3'-5'-korrekturlæsningsaktivitet, hvor primerne ifølge mindst et af trin (ii) og (iii) omfatter nucleinsyremarkører, således at hvert mærket nucleinsyremolekyle er unikt, for derved at generere unikt mærkede nucleinsyremolekyler.
11. Fremgangsmåden ifølge krav 10, hvor tilsætning af en polynukleotid-ende omfatter anvendelsen af en terminal transferase.
12. Fremgangsmåde ifølge et hvilket som helst af kravene 1-11, hvor de mærkede nucleinsyremolekyler er udsat for en hybrid-capture- fremgangsmåde forud for PCR eller forud for sekventering, hvor de mærkede nucleinsyremolekyler er dannet fra en enkelt art, hvor de mærkede nucleinsyremolekyler er dannet fra en enkelt celle, hvor de mærkede nucleinsyremolekyler er dannet fra to eller flere organismer, eller hvor de mærkede nucleinsyremolekyler er dannet af to eller flere arter, hvor de mærkede nucleinsyremolekyler er dannet ud fra en population af mikrober, og hvor information om antallet af genomiske kopier der er opnået for forskellige arter af populationen sammenlignes for at bestemme det relative antal af de forskellige arter i populationen.
13. Fremgangsmåde ifølge et hvilket som helst af kravene 1-12, hvor markørsekvenserne yderligere omfatter en prøve-markør.
14. Fremgangsmåden ifølge krav 13, hvor de mærkede nucleinsyremolekyler er samlet med et antal mærkede nucleinsyremolekyler der har en forskellig prøvemarkør forud for PCR-amplifikation eller forud for sekventering.
15. Fremgangsmåden ifølge krav 14, der yderligere omfatter dekonvolutering af de markør-associerede sekvensreads ved at gruppere de markør-associerede sekvensreads ifølge prøve-markør.
16. Fremgangsmåden ifølge krav 1, hvor stedet på et genom der er associeret med det genomiske materiale er identisk med undersekvensen af en markørassocieret sekvensread der svarer til en art af nucleinsyremolekyle.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40606710P | 2010-10-22 | 2010-10-22 | |
| US201161510579P | 2011-07-22 | 2011-07-22 | |
| PCT/US2011/057350 WO2012054873A2 (en) | 2010-10-22 | 2011-10-21 | Varietal counting of nucleic acids for obtaining genomic copy number information |
| US13/278,333 US9404156B2 (en) | 2010-10-22 | 2011-10-21 | Varietal counting of nucleic acids for obtaining genomic copy number information |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK2630263T3 true DK2630263T3 (da) | 2018-07-23 |
| DK2630263T4 DK2630263T4 (da) | 2022-02-14 |
Family
ID=45975922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11835243.4T DK2630263T4 (da) | 2010-10-22 | 2011-10-21 | Varital tælling af nucleinsyrer for at opnå information om antal genomiske kopier |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US9404156B2 (da) |
| EP (4) | EP4328321A3 (da) |
| AU (1) | AU2011316807C1 (da) |
| CA (4) | CA2815076C (da) |
| DK (1) | DK2630263T4 (da) |
| ES (1) | ES2688458T5 (da) |
| HU (1) | HUE039766T2 (da) |
| PL (1) | PL2630263T5 (da) |
| PT (1) | PT2630263T (da) |
| SI (1) | SI2630263T2 (da) |
| TR (1) | TR201810530T4 (da) |
| WO (1) | WO2012054873A2 (da) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005009324D1 (de) | 2005-04-06 | 2008-10-09 | Maurice Stroun | Methode zur Krebsdiagnose mittels Nachweis von DNA und RNA im Kreislauf |
| US9085798B2 (en) | 2009-04-30 | 2015-07-21 | Prognosys Biosciences, Inc. | Nucleic acid constructs and methods of use |
| US9677139B2 (en) | 2009-12-11 | 2017-06-13 | Cold Spring Harbor Laboratory | Genetic markers indicative of a cancer patient response to trastuzumab (herceptin) |
| PT2556171E (pt) | 2010-04-05 | 2015-12-21 | Prognosys Biosciences Inc | Ensaios biológicos codificados espacialmente |
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| US20190300945A1 (en) | 2010-04-05 | 2019-10-03 | Prognosys Biosciences, Inc. | Spatially Encoded Biological Assays |
| AU2011242576B2 (en) | 2010-04-23 | 2016-03-31 | Cold Spring Harbor Laboratory | Novel structurally designed shRNAs |
| HUE039766T2 (hu) | 2010-10-22 | 2019-02-28 | Cold Spring Harbor Laboratory | Nukleinsavak változatainak megszámlálása genom kópiaszám információ megszerzésére |
| US9260753B2 (en) | 2011-03-24 | 2016-02-16 | President And Fellows Of Harvard College | Single cell nucleic acid detection and analysis |
| GB201106254D0 (en) | 2011-04-13 | 2011-05-25 | Frisen Jonas | Method and product |
| DK3246416T3 (da) | 2011-04-15 | 2024-09-02 | Univ Johns Hopkins | Sikkert sekventeringssystem |
| EP2814959B1 (en) | 2012-02-17 | 2018-01-17 | Fred Hutchinson Cancer Research Center | Compositions and methods for accurately identifying mutations |
| US20150011396A1 (en) | 2012-07-09 | 2015-01-08 | Benjamin G. Schroeder | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
| US11913065B2 (en) | 2012-09-04 | 2024-02-27 | Guardent Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| US10876152B2 (en) | 2012-09-04 | 2020-12-29 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| KR102393608B1 (ko) | 2012-09-04 | 2022-05-03 | 가던트 헬쓰, 인크. | 희귀 돌연변이 및 카피수 변이를 검출하기 위한 시스템 및 방법 |
| US20160040229A1 (en) | 2013-08-16 | 2016-02-11 | Guardant Health, Inc. | Systems and methods to detect rare mutations and copy number variation |
| DK3511423T4 (da) | 2012-10-17 | 2024-07-29 | Spatial Transcriptomics Ab | Fremgangsmåder og produkt til optimering af lokaliseret eller rumlig detektion af genekspression i en vævsprøve |
| ES2886507T5 (es) | 2012-10-29 | 2024-11-15 | Univ Johns Hopkins | Prueba de Papanicolaou para cánceres de ovario y de endometrio |
| WO2014144092A1 (en) | 2013-03-15 | 2014-09-18 | Nugen Technologies, Inc. | Sequential sequencing |
| SG10201708498VA (en) | 2013-04-17 | 2017-11-29 | Agency Science Tech & Res | Method for generating extended sequence reads |
| EP4234716A3 (en) | 2013-06-25 | 2023-12-06 | Prognosys Biosciences, Inc. | Methods for determining spatial patterns of biological targets in a sample |
| WO2015073711A1 (en) | 2013-11-13 | 2015-05-21 | Nugen Technologies, Inc. | Compositions and methods for identification of a duplicate sequencing read |
| EP3378952B1 (en) | 2013-12-28 | 2020-02-05 | Guardant Health, Inc. | Methods and systems for detecting genetic variants |
| CA2938080A1 (en) | 2014-01-27 | 2015-07-30 | The General Hospital Corporation | Methods of preparing nucleic acids for sequencing |
| EP3169799B1 (en) | 2014-07-15 | 2019-09-04 | Qiagen Sciences, LLC | Semi-random barcodes for nucleic acid analysis |
| WO2016019360A1 (en) * | 2014-08-01 | 2016-02-04 | Dovetail Genomics Llc | Tagging nucleic acids for sequence assembly |
| US10102337B2 (en) | 2014-08-06 | 2018-10-16 | Nugen Technologies, Inc. | Digital measurements from targeted sequencing |
| EP3204521B1 (en) * | 2014-10-10 | 2021-06-02 | Cold Spring Harbor Laboratory | Random nucleotide mutation for nucleotide template counting and assembly |
| US10233490B2 (en) | 2014-11-21 | 2019-03-19 | Metabiotech Corporation | Methods for assembling and reading nucleic acid sequences from mixed populations |
| DK3792378T3 (da) * | 2015-02-04 | 2023-11-27 | Univ British Columbia | Fremgangsmåder og anordninger til analyse af partikler |
| EP4030437A1 (en) | 2015-02-17 | 2022-07-20 | Dovetail Genomics, LLC | Nucleic acid sequence assembly |
| GB2554572B (en) | 2015-03-26 | 2021-06-23 | Dovetail Genomics Llc | Physical linkage preservation in DNA storage |
| EP4119677B1 (en) | 2015-04-10 | 2023-06-28 | Spatial Transcriptomics AB | Spatially distinguished, multiplex nucleic acid analysis of biological specimens |
| WO2017027653A1 (en) | 2015-08-11 | 2017-02-16 | The Johns Hopkins University | Assaying ovarian cyst fluid |
| US11302416B2 (en) | 2015-09-02 | 2022-04-12 | Guardant Health | Machine learning for somatic single nucleotide variant detection in cell-free tumor nucleic acid sequencing applications |
| CN108603190B (zh) | 2015-09-08 | 2023-05-23 | 美国冷泉港实验室 | 使用经破碎的核苷酸的高通量多重测序确定基因拷贝数 |
| EP3365445B1 (en) | 2015-10-19 | 2023-05-31 | Dovetail Genomics, LLC | Methods for genome assembly, haplotype phasing, and target independent nucleic acid detection |
| JP2019507585A (ja) | 2015-12-17 | 2019-03-22 | ガーダント ヘルス, インコーポレイテッド | 無細胞dnaの分析による腫瘍遺伝子コピー数を決定するための方法 |
| US10975417B2 (en) | 2016-02-23 | 2021-04-13 | Dovetail Genomics, Llc | Generation of phased read-sets for genome assembly and haplotype phasing |
| EP4488686A3 (en) | 2016-04-14 | 2025-04-30 | Guardant Health, Inc. | Methods for early detection of cancer |
| US11384382B2 (en) | 2016-04-14 | 2022-07-12 | Guardant Health, Inc. | Methods of attaching adapters to sample nucleic acids |
| EP4269616A3 (en) * | 2016-05-02 | 2024-02-14 | Becton, Dickinson and Company | Accurate molecular barcoding |
| EP3455356B1 (en) | 2016-05-13 | 2021-08-04 | Dovetail Genomics LLC | Recovering long-range linkage information from preserved samples |
| US9850523B1 (en) | 2016-09-30 | 2017-12-26 | Guardant Health, Inc. | Methods for multi-resolution analysis of cell-free nucleic acids |
| EP3792922A1 (en) | 2016-09-30 | 2021-03-17 | Guardant Health, Inc. | Methods for multi-resolution analysis of cell-free nucleic acids |
| US10190155B2 (en) | 2016-10-14 | 2019-01-29 | Nugen Technologies, Inc. | Molecular tag attachment and transfer |
| US10650312B2 (en) | 2016-11-16 | 2020-05-12 | Catalog Technologies, Inc. | Nucleic acid-based data storage |
| KR20230054484A (ko) | 2016-11-16 | 2023-04-24 | 카탈로그 테크놀로지스, 인크. | 핵산-기반 데이터 저장용 시스템 |
| IL302912A (en) * | 2016-12-22 | 2023-07-01 | Guardant Health Inc | Methods and systems for analyzing nucleic acid molecules |
| EP3571615B1 (en) | 2017-01-20 | 2024-01-24 | Sequenom, Inc. | Methods for non-invasive assessment of genetic alterations |
| WO2018183942A1 (en) | 2017-03-31 | 2018-10-04 | Grail, Inc. | Improved library preparation and use thereof for sequencing-based error correction and/or variant identification |
| US12492430B2 (en) | 2017-04-11 | 2025-12-09 | Tecan Genomics, Inc. | Library quantitation and qualification |
| EP3431611A1 (en) * | 2017-07-21 | 2019-01-23 | Menarini Silicon Biosystems S.p.A. | Improved method and kit for the generation of dna libraries for massively parallel sequencing |
| CN111868260B (zh) | 2017-08-07 | 2025-02-21 | 约翰斯霍普金斯大学 | 用于评估和治疗癌症的方法和材料 |
| US11099202B2 (en) | 2017-10-20 | 2021-08-24 | Tecan Genomics, Inc. | Reagent delivery system |
| WO2019178220A1 (en) * | 2018-03-13 | 2019-09-19 | Grail, Inc. | Identifying copy number aberrations |
| CA3094077A1 (en) | 2018-03-16 | 2019-09-19 | Catalog Technologies, Inc. | Chemical methods for nucleic acid-based data storage |
| KR20210029147A (ko) | 2018-05-16 | 2021-03-15 | 카탈로그 테크놀로지스, 인크. | 핵산-기반 데이터를 저장하기 위한 조성물 및 방법 |
| AU2019315604B2 (en) | 2018-08-03 | 2025-04-17 | Catolog Technologies, Inc | Systems and methods for storing and reading nucleic acid-based data with error protection |
| EP3918089B1 (en) | 2019-01-31 | 2025-01-15 | Guardant Health, Inc. | Method for isolating and sequencing cell-free dna |
| EP3966823A1 (en) | 2019-05-09 | 2022-03-16 | Catalog Technologies, Inc. | Data structures and operations for searching, computing, and indexing in dna-based data storage |
| AU2020341808A1 (en) * | 2019-09-06 | 2022-03-24 | Honeycomb Biotechnologies, Inc. | Methods and systems for RNA-seq profiling |
| JP7726874B2 (ja) * | 2019-10-11 | 2025-08-20 | カタログ テクノロジーズ, インコーポレイテッド | 核酸セキュリティーおよび認証 |
| WO2021133842A1 (en) | 2019-12-23 | 2021-07-01 | 10X Genomics, Inc. | Compositions and methods for using fixed biological samples in partition-based assays |
| US11702693B2 (en) | 2020-01-21 | 2023-07-18 | 10X Genomics, Inc. | Methods for printing cells and generating arrays of barcoded cells |
| US11732299B2 (en) | 2020-01-21 | 2023-08-22 | 10X Genomics, Inc. | Spatial assays with perturbed cells |
| US20210230681A1 (en) | 2020-01-24 | 2021-07-29 | 10X Genomics, Inc. | Methods for spatial analysis using proximity ligation |
| CN113275053A (zh) | 2020-02-03 | 2021-08-20 | 帝肯基因组学公司 | 试剂存储系统 |
| US11835462B2 (en) | 2020-02-11 | 2023-12-05 | 10X Genomics, Inc. | Methods and compositions for partitioning a biological sample |
| CN115516108A (zh) | 2020-02-14 | 2022-12-23 | 约翰斯霍普金斯大学 | 评估核酸的方法和材料 |
| US11211147B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Estimation of circulating tumor fraction using off-target reads of targeted-panel sequencing |
| US11475981B2 (en) | 2020-02-18 | 2022-10-18 | Tempus Labs, Inc. | Methods and systems for dynamic variant thresholding in a liquid biopsy assay |
| US11211144B2 (en) | 2020-02-18 | 2021-12-28 | Tempus Labs, Inc. | Methods and systems for refining copy number variation in a liquid biopsy assay |
| US11926863B1 (en) | 2020-02-27 | 2024-03-12 | 10X Genomics, Inc. | Solid state single cell method for analyzing fixed biological cells |
| AU2021271639A1 (en) | 2020-05-11 | 2022-12-08 | Catalog Technologies, Inc. | Programs and functions in DNA-based data storage |
| WO2021236929A1 (en) | 2020-05-22 | 2021-11-25 | 10X Genomics, Inc. | Simultaneous spatio-temporal measurement of gene expression and cellular activity |
| US12265079B1 (en) | 2020-06-02 | 2025-04-01 | 10X Genomics, Inc. | Systems and methods for detecting analytes from captured single biological particles |
| CN114582419B (zh) * | 2022-01-29 | 2023-02-10 | 苏州大学 | 一种基于滑动窗口的基因序列多聚腺苷酸尾巴提取方法 |
| CN119242777B (zh) * | 2024-12-03 | 2025-02-25 | 四川大学华西医院 | 一种超低起始量dna基因突变、扩增和染色体cnv共检测方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080540A (en) | 1990-04-20 | 2000-06-27 | Cold Spring Harbor Laboratory | Cloning of mammalian genes in microbial organisms and methods for pharmacological screening |
| US5639603A (en) | 1991-09-18 | 1997-06-17 | Affymax Technologies N.V. | Synthesizing and screening molecular diversity |
| US6013445A (en) * | 1996-06-06 | 2000-01-11 | Lynx Therapeutics, Inc. | Massively parallel signature sequencing by ligation of encoded adaptors |
| US5846719A (en) | 1994-10-13 | 1998-12-08 | Lynx Therapeutics, Inc. | Oligonucleotide tags for sorting and identification |
| JP2001521754A (ja) | 1997-10-30 | 2001-11-13 | コールド スプリング ハーバー ラボラトリー | Dna識別のためのプローブアレイ及びプローブアレイの使用方法 |
| US7700324B1 (en) * | 1998-11-03 | 2010-04-20 | The Johns Hopkins University School Of Medicine | Methylated CpG island amplification (MCA) |
| US20040110153A1 (en) * | 2002-12-10 | 2004-06-10 | Affymetrix, Inc. | Compleixity management of genomic DNA by semi-specific amplification |
| GEP20125384B (en) | 2003-05-23 | 2012-01-25 | Cold Spring Harbor Lab | Representations of nucleotide sequences |
| ES2281743T3 (es) * | 2003-12-16 | 2007-10-01 | Bayer Healthcare Llc | Ensayo para detectar el estado de metilacion por extension con iniciadores especificos de metilacion (mspe). |
| US20080261204A1 (en) † | 2004-01-23 | 2008-10-23 | Lingvitae As | Polynucleotide Ligation Reactions |
| US7622281B2 (en) | 2004-05-20 | 2009-11-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for clonal amplification of nucleic acid |
| US20060035258A1 (en) | 2004-08-06 | 2006-02-16 | Affymetrix, Inc. | Methods for identifying DNA copy number changes |
| EP1647600A3 (en) | 2004-09-17 | 2006-06-28 | Affymetrix, Inc. (A US Entity) | Methods for identifying biological samples by addition of nucleic acid bar-code tags |
| EP1904521B1 (en) | 2005-07-08 | 2013-08-21 | Universidad Nacional Autonoma De Mexico Instituto | Novel bacterial proteins with pesticidal activity |
| US20070020640A1 (en) † | 2005-07-21 | 2007-01-25 | Mccloskey Megan L | Molecular encoding of nucleic acid templates for PCR and other forms of sequence analysis |
| EP1924704B1 (en) * | 2005-08-02 | 2011-05-25 | Rubicon Genomics, Inc. | Compositions and methods for processing and amplification of dna, including using multiple enzymes in a single reaction |
| AT502823B1 (de) * | 2005-11-29 | 2007-06-15 | Seitz Alexander Dr | Polynukleotid-amplifikation |
| CA2633339C (en) | 2005-12-14 | 2019-03-19 | Cold Spring Harbor Laboratory | Methods for assessing probabilistic measures of clinical outcome using genomic profiling |
| CA2633203A1 (en) | 2005-12-14 | 2007-06-21 | Michael H. Wigler | Use of roma for characterizing genomic rearrangements |
| US7537897B2 (en) | 2006-01-23 | 2009-05-26 | Population Genetics Technologies, Ltd. | Molecular counting |
| US20090137402A1 (en) | 2006-10-11 | 2009-05-28 | San Ming Wang | Ditag genome scanning technology |
| DE102008025656B4 (de) † | 2008-05-28 | 2016-07-28 | Genxpro Gmbh | Verfahren zur quantitativen Analyse von Nukleinsäuren, Marker dafür und deren Verwendung |
| EA020593B1 (ru) * | 2009-01-13 | 2014-12-30 | Флуидигм Корпорейшн | Анализ нуклеиновых кислот, полученных из единичных клеток |
| WO2010085343A1 (en) | 2009-01-23 | 2010-07-29 | Cold Spring Harbor Laboratory | Methods and arrays for profiling dna methylation |
| US8450063B2 (en) * | 2009-01-28 | 2013-05-28 | Fluidigm Corporation | Determination of copy number differences by amplification |
| US9677139B2 (en) | 2009-12-11 | 2017-06-13 | Cold Spring Harbor Laboratory | Genetic markers indicative of a cancer patient response to trastuzumab (herceptin) |
| AU2011242576B2 (en) | 2010-04-23 | 2016-03-31 | Cold Spring Harbor Laboratory | Novel structurally designed shRNAs |
| ES2690753T3 (es) | 2010-09-21 | 2018-11-22 | Agilent Technologies, Inc. | Aumento de la confianza en las identificaciones de alelos con el recuento molecular |
| HUE039766T2 (hu) | 2010-10-22 | 2019-02-28 | Cold Spring Harbor Laboratory | Nukleinsavak változatainak megszámlálása genom kópiaszám információ megszerzésére |
| DK3246416T3 (da) | 2011-04-15 | 2024-09-02 | Univ Johns Hopkins | Sikkert sekventeringssystem |
-
2011
- 2011-10-21 HU HUE11835243A patent/HUE039766T2/hu unknown
- 2011-10-21 PL PL11835243T patent/PL2630263T5/pl unknown
- 2011-10-21 AU AU2011316807A patent/AU2011316807C1/en active Active
- 2011-10-21 DK DK11835243.4T patent/DK2630263T4/da active
- 2011-10-21 PT PT118352434T patent/PT2630263T/pt unknown
- 2011-10-21 EP EP23197909.7A patent/EP4328321A3/en active Pending
- 2011-10-21 EP EP11835243.4A patent/EP2630263B2/en active Active
- 2011-10-21 CA CA2815076A patent/CA2815076C/en active Active
- 2011-10-21 WO PCT/US2011/057350 patent/WO2012054873A2/en not_active Ceased
- 2011-10-21 CA CA3080686A patent/CA3080686C/en active Active
- 2011-10-21 CA CA3080699A patent/CA3080699A1/en active Pending
- 2011-10-21 EP EP18169127.0A patent/EP3461914A1/en not_active Withdrawn
- 2011-10-21 SI SI201131525T patent/SI2630263T2/sl unknown
- 2011-10-21 CA CA3210003A patent/CA3210003A1/en active Pending
- 2011-10-21 EP EP19201353.0A patent/EP3702475A1/en not_active Withdrawn
- 2011-10-21 ES ES11835243T patent/ES2688458T5/es active Active
- 2011-10-21 TR TR2018/10530T patent/TR201810530T4/tr unknown
- 2011-10-21 US US13/278,333 patent/US9404156B2/en active Active
-
2016
- 2016-03-07 US US15/063,278 patent/US10947589B2/en active Active
-
2019
- 2019-02-07 US US16/269,818 patent/US12234510B2/en active Active
-
2025
- 2025-01-31 US US19/042,371 patent/US20250361556A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250361556A1 (en) | Varietal counting of nucleic acids for obtaining genomic copy number information | |
| US12435373B2 (en) | Identification of polymorphic sequences in mixtures of genomic DNA | |
| Plongthongkum et al. | Advances in the profiling of DNA modifications: cytosine methylation and beyond | |
| CN108779487A (zh) | 用于检测甲基化状态的核酸和方法 | |
| US20190309352A1 (en) | Multimodal assay for detecting nucleic acid aberrations | |
| CN105518151A (zh) | 循环核酸肿瘤标志物的鉴别和用途 | |
| EP3080303B1 (en) | Methods for full-length amplification of double-stranded linear nucleic acids of unknown sequences | |
| JP2004504059A (ja) | 転写された遺伝子を分析、及び同定するための方法、及びフインガープリント法 | |
| Barault et al. | Laboratory methods in epigenetic epidemiology | |
| HK40037263A (en) | Varietal counting of nucleic acids for obtaining genomic copy number information | |
| HK40006962A (en) | Varietal counting of nucleic acids for obtaining genomic copy number information | |
| US20220145368A1 (en) | Methods for noninvasive prenatal testing of fetal abnormalities | |
| EA047854B1 (ru) | Способы неинвазивного пренатального тестирования аномалий плода | |
| Gentien et al. | Microarrays-Based Molecular Profiling to Identify Genomic Alterations | |
| Rodriguez et al. | Special Techniques |